Serum S-100B adds incremental value for the prediction of symptomatic intracranial hemorrhage and brain edema after acute ischemic stroke

Honegger, Tim; Schweizer, Juliane; Bicvic, Antonela; Westphal, Laura P; Schütz, Valerie; Inauen, Corinne; Pokorny, Thomas; Bracher, Katja; Arnold, Marcel; Fischer, Urs; Bonati, Leo H.; Marchis, Gian Marco De; Nedeltchev, Krassen; Kahles, Timo; Cereda, Carlo; Kägi, Georg; Montaner, Joan; Bustamante, Alejandro; Palà, Elena; Ntaios, George; Foerch, Christian; Luft, Andreas R.; Spanaus, Katharina; Saleh, Lanja; Eckardstein, Arnold von; Arnold, Markus; Katan, Mira

doi:10.1177/23969873221145391

Cited by 6 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 26 ] Damage to the blood–brain barrier after stroke is associated with neuroinflammation. [ 27 ] Serum biomarkers of blood–brain barrier dysfunction, such as S-100B, [ 28 ] astrocytic endothelin-1, [ 29 ] matrix metalloproteinase-9 and cellular-fibronectin, [ 30 ] and serum inflammatory biomarkers, such as procalcitonin and neutrophil counts, [ 31 ] neutrophil-to-lymphocyte ratio, [ 32 ] E-selectin, [ 33 ] brain natriuretic peptide, [ 34 ] and NOD-like receptor protein 3, [ 35 ] were reported to be associated with the development of brain edema after stroke. A number of multivariable models have been developed for predicting malignant brain edema, containing a combination of clinical characteristics, imaging features, and serum biomarkers, with the most commonly included factors being NIHSS score, large infarction, and revascularization status.…”

Section: Prediction and Prevention Of Malignant Brain Edemamentioning

confidence: 99%

Definition, prediction, prevention and management of patients with severe ischemic stroke and large infarction

Hua,

Liu,

2023

Chinese Medical Journal

View full text Add to dashboard Cite

Severe ischemic stroke carries a high rate of disability and death. The severity of stroke is often assessed by the degree of neurological deficits or the extent of brain infarct, defined as severe stroke and large infarction, respectively. Critically severe stroke is a life-threatening condition that requires neurocritical care or neurosurgical intervention, which includes stroke with malignant brain edema, a leading cause of death during the acute phase, and stroke with severe complications of other vital systems. Early prediction of high-risk patients with critically severe stroke would inform early prevention and treatment to interrupt the malignant course to fatal status. Selected patients with severe stroke could benefit from intravenous thrombolysis and endovascular treatment in improving functional outcome. There is insufficient evidence to inform dual antiplatelet therapy and the timing of anticoagulation initiation after severe stroke. Decompressive hemicraniectomy (DHC) <48 h improves survival in patients aged <60 years with large hemispheric infarction. Studies are ongoing to provide evidence to inform more precise prediction of malignant brain edema, optimal indications for acute reperfusion therapies and neurosurgery, and the individualized management of complications and secondary prevention. We present an evidence-based review for severe ischemic stroke, with the aims of proposing operational definitions, emphasizing the importance of early prediction and prevention of the evolution to critically severe status, summarizing specialized treatment for severe stroke, and proposing directions for future research.

show abstract

Section: Prediction and Prevention Of Malignant Brain Edemamentioning

confidence: 99%

Definition, prediction, prevention and management of patients with severe ischemic stroke and large infarction

Hua,

Liu,

2023

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

Ginkgo biloba active compounds can modulate the development of acute mountain sickness and ischemic stroke as discovered by network pharmacology and molecular docking

Guo,

Kang,

et al. 2024

iLABMED

View full text Add to dashboard Cite

BackgroundA combination of molecular docking, molecular dynamics simulations, and herbal network pharmacology was used to investigate the shared key targets and potential mechanisms underlying the preventive effects of Ginkgo biloba active compounds against acute mountain sickness (AMS) and ischemic stroke (IS).Material and MethodsThe Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was used to screen the main active compounds of Ginkgo biloba and their corresponding targets. We obtained AMS‐related genes by mining several databases and cross‐correlated them with key active compounds of Ginkgo biloba to identify relevant action targets for treating AMS. The STRING database was used to construct a protein–protein interaction network of the effect of Ginkgo biloba active compounds on AMS targets. The expression of genes in the network was analyzed in an IS dataset to identify common key targets of Ginkgo biloba active compounds for both AMS and IS prevention.ResultsThe intersection between the targets of Ginkgo biloba active compounds and AMS‐related genes identified 43 overlapping genes. Analysis of the protein–protein interaction network showed that VEGFA, TP53, SERPINE1, and PTGS2 were among the key hub genes. Analysis of the IS dataset identified significant differences in the expression levels of CAT, TP53, CXCL8, NFKBIA, and PTGS2. These genes were used to construct a visual nomogram prediction model for IS prognosis with promising clinical implications. Molecular docking and molecular dynamics simulations indicated that sesamin stably targeted and bound to PTGS2.ConclusionsActive ingredients of Ginkgo biloba, including luteolin, quercetin, and sesamin, have the potential to modulate the development of AMS and IS through targeted interactions with key proteins, including TP53, CXCL8, NFKBIA, PTGS2, and CAT.

show abstract

Use of biomarkers for predicting a malignant course in acute ischemic stroke: an observational case–control study

Guimarães de Almeida Barros,

Roquim e Silva,

Pessoa

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Acute ischemic stroke is a sudden neurological event caused by brain ischemia. Patients with large vessel occlusion are at high risk of developing significant cerebral edema, which can lead to rapid neurological decline. The optimal timing for decompressive hemicraniectomy to prevent further brain damage is still uncertain. This study aimed to identify potential predictors of severe brain edema. The data indicate that specific cytokines may help identify patients with a higher risk of developing life-threatening brain swelling in the early phase post-stroke. The association between a positive biomarker and the outcome was calculated, and three biomarkers—S100B protein, MMP-9, and IL-10—were found to be significantly associated with malignant edema. A model was derived for early predicting malignant cerebral edema, including S100B protein and IL-1 beta. These findings suggest that molecular biomarkers related to the ischemic cascade may be a helpful way of predicting the development of malignant cerebral edema in ischemic stroke patients, potentially widening the time window for intervention and assisting in decision-making. In conclusion, this study provides insights into the molecular mechanisms of severe brain edema and highlights the potential use of biomarkers in predicting the course of ischemic stroke.

show abstract

Serum S-100B adds incremental value for the prediction of symptomatic intracranial hemorrhage and brain edema after acute ischemic stroke

Cited by 6 publications

References 46 publications

Definition, prediction, prevention and management of patients with severe ischemic stroke and large infarction

Definition, prediction, prevention and management of patients with severe ischemic stroke and large infarction

Ginkgo biloba active compounds can modulate the development of acute mountain sickness and ischemic stroke as discovered by network pharmacology and molecular docking

Use of biomarkers for predicting a malignant course in acute ischemic stroke: an observational case–control study

Contact Info

Product

Resources

About